Inhibition of the angiotensin II type 2 receptor AT
Analgesics
/ pharmacology
Angiotensin II
/ chemistry
Angiotensin II Type 2 Receptor Blockers
/ therapeutic use
Apoptosis
Benzhydryl Compounds
/ chemistry
Brain Neoplasms
/ drug therapy
Drug Repositioning
Glioblastoma
/ drug therapy
Humans
Isoquinolines
/ chemistry
Protein Conformation, alpha-Helical
Receptor, Angiotensin, Type 2
/ chemistry
Tumor Burden
/ drug effects
angiotensin II
glioblastoma
renin angiotensin system
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
09 08 2022
09 08 2022
Historique:
entrez:
2
8
2022
pubmed:
3
8
2022
medline:
5
8
2022
Statut:
ppublish
Résumé
Glioblastoma (GBM) is an aggressive malignant primary brain tumor with limited therapeutic options. We show that the angiotensin II (AngII) type 2 receptor (AT
Identifiants
pubmed: 35917342
doi: 10.1073/pnas.2116289119
pmc: PMC9371711
doi:
Substances chimiques
Analgesics
0
Angiotensin II Type 2 Receptor Blockers
0
Benzhydryl Compounds
0
EMA400
0
Isoquinolines
0
Receptor, Angiotensin, Type 2
0
Angiotensin II
11128-99-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2116289119Subventions
Organisme : National Institute of Health
ID : R35GM127086
Organisme : NIGMS NIH HHS
ID : R35 GM127086
Pays : United States
Organisme : National Institute of Health
ID : UG3NS116929
Organisme : NIGMS NIH HHS
ID : AGM-12006
Pays : United States
Organisme : NCI NIH HHS
ID : ACB-12002
Pays : United States
Organisme : ODCDC CDC HHS
ID : S10 OD012289
Pays : United States
Organisme : NINDS NIH HHS
ID : UH3 NS116929
Pays : United States
Références
ACS Chem Biol. 2014 Jul 18;9(7):1420-5
pubmed: 24787922
Mol Pharm. 2014 Aug 4;11(8):2755-63
pubmed: 24983928
Biopharm Drug Dispos. 2020 Apr;41(4-5):166-183
pubmed: 32190910
Oncotarget. 2014 Sep 30;5(18):8052-82
pubmed: 25211298
Gynecol Oncol. 2014 Oct;135(1):108-17
pubmed: 25014541
Int J Pharm. 2016 Sep 25;511(2):794-803
pubmed: 27484836
Cell Death Dis. 2016 Oct 20;7(10):e2427
pubmed: 27763643
Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14849-54
pubmed: 21852574
Eur J Neurol. 2015 Sep;22(9):1304-9
pubmed: 26053493
Nat Rev Cancer. 2010 Nov;10(11):745-59
pubmed: 20966920
Bioorg Med Chem Lett. 2021 Jul 1;43:128086
pubmed: 33965531
Lancet. 2014 May 10;383(9929):1637-1647
pubmed: 24507377
J Drug Target. 2015;23(9):832-46
pubmed: 25856302
Curr Opin Nephrol Hypertens. 2012 Mar;21(2):142-6
pubmed: 22257799
Nature. 2017 Apr 20;544(7650):327-332
pubmed: 28379944
Physiol Rev. 2006 Jul;86(3):747-803
pubmed: 16816138
Oncogene. 2019 Mar;38(13):2320-2336
pubmed: 30478450
Nat Struct Mol Biol. 2018 Jul;25(7):570-576
pubmed: 29967536
Structure. 2020 Apr 7;28(4):418-425.e4
pubmed: 31899086
Cancer Biol Ther. 2015;16(2):307-16
pubmed: 25756513
Cell Mol Neurobiol. 2012 Nov;32(8):1353-65
pubmed: 22843099
J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):227-33
pubmed: 23934336
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Chemistry. 2020 Aug 21;26(47):10690-10694
pubmed: 32691857
Br J Cancer. 2005 Apr 11;92(7):1247-52
pubmed: 15785746
Inflammopharmacology. 2020 Feb;28(1):187-199
pubmed: 31321575
J Biol Chem. 2005 May 6;280(18):18237-44
pubmed: 15746093
Nat Commun. 2014 Jun 19;5:4196
pubmed: 24943270
Expert Opin Ther Targets. 2015 Jan;19(1):25-35
pubmed: 25315162
J Neurooncol. 2018 May;138(1):1-15
pubmed: 29450812
J Renin Angiotensin Aldosterone Syst. 2011 Mar;12(1):1-7
pubmed: 20603272
Cancer Biol Ther. 2010 Feb;9(4):277-85
pubmed: 20026904
Front Surg. 2016 Sep 27;3:51
pubmed: 27730123
Nucleic Acids Res. 2012 Jan;40(Database issue):D370-6
pubmed: 21890895
Nat Struct Mol Biol. 2018 Jan;25(1):4-12
pubmed: 29323277
FASEB J. 2020 Dec;34(12):16645-16661
pubmed: 33131100
Pain Med. 2013 May;14(5):692-705
pubmed: 23489258
Eur J Pain. 2013 Aug;17(7):1012-26
pubmed: 23255326